Background: Elevated antibodies against Chlamydia pneumoniae have been associated with coronary artery disease. In patients undergoing percutaneous coronary angioplasty, we therefore investigated the effect of roxithr...Background: Elevated antibodies against Chlamydia pneumoniae have been associated with coronary artery disease. In patients undergoing percutaneous coronary angioplasty, we therefore investigated the effect of roxithromycin on symptomatic restenosis and determined antichlamydial antibodies as well as inflammatory and immunological parameters. Methods: A total of 327 patients undergoing coronary angioplasty were randomized to roxithromycin or placebo and followed-up for 1 year. Antibodies were determined by microimmunofluorescence and enzyme-linked immunosorbent assay; C-reactive protein, interleukin-10, tumor necrosis factor-α (TNF-α ), and eotaxin were determined by enzyme-linked immunosorbent assay. Results: Although the frequency of restenosis was not affected by roxithromycin(25 restenoses vs 32 in the control group), antichlamydial antibodies increased during follow-up(anti-CP IgG + 12± 2% , P< .001). Concentrations of TNF-α and eotaxin increased as well(TNF-α + 9± 1% and eotaxin + 10± 2% )and correlated with antichlamydial antibody concentrations(TNF-α , r=0.23, P=.02; eotaxin, r=0.32, P=.002). Conclusions: Treatment with roxithromycin was not associated with a reduction of symptomatic restenoses. During follow-up, a marked increase in antichlamydial antibodies, TNF-α , and eotaxin was observed, suggesting that angioplasty-induced plaque rupture induces a specific immunological response without activation of inflammatory mechanisms as represented by C-reactive protein. Whether this mechanism occurs in all plaque ruptures remains to be determined.展开更多
目的：了解南昌大学第三附属医院耐碳青霉烯类抗菌药物的肺炎克雷伯菌（CRKP）的耐药状况。方法将2009年1月至2013年12月临床送检合格标本，采用西门子Micro Scan Walk Away40 Plus 微生物分析仪及配套的革兰阴性菌鉴定药敏板，进行菌...目的：了解南昌大学第三附属医院耐碳青霉烯类抗菌药物的肺炎克雷伯菌（CRKP）的耐药状况。方法将2009年1月至2013年12月临床送检合格标本，采用西门子Micro Scan Walk Away40 Plus 微生物分析仪及配套的革兰阴性菌鉴定药敏板，进行菌株鉴定与药敏试验，结果判读按照CLSI的标准，将分离到的肺炎克雷伯菌进行筛选，再筛选出CRKP。结果从检测到的769株肺炎克雷伯菌中筛选到17株CRKP。 CRKP发生率2009年为0.0%，2013年上升到4.3%。CRKP对加替沙星耐药率最低占33.3％，对氨苄青霉素、阿莫西林/棒酸、头孢唑啉、环丙沙星、替卡西林/棒酸、耐药率高达100.0％；头孢类除孢噻肟、头孢哌酮/舒巴坦耐药率在50.0%以下，其余的均在50.0%～100.0%。美洛配能亚胺培南耐药率高达80.0%以上。结论 CRKP对常用抗菌药物有严重的耐药趋势，对重症患者、感染严重患者，不能单凭经验用药，应依据药敏试验选择抗菌药物。展开更多
文摘Background: Elevated antibodies against Chlamydia pneumoniae have been associated with coronary artery disease. In patients undergoing percutaneous coronary angioplasty, we therefore investigated the effect of roxithromycin on symptomatic restenosis and determined antichlamydial antibodies as well as inflammatory and immunological parameters. Methods: A total of 327 patients undergoing coronary angioplasty were randomized to roxithromycin or placebo and followed-up for 1 year. Antibodies were determined by microimmunofluorescence and enzyme-linked immunosorbent assay; C-reactive protein, interleukin-10, tumor necrosis factor-α (TNF-α ), and eotaxin were determined by enzyme-linked immunosorbent assay. Results: Although the frequency of restenosis was not affected by roxithromycin(25 restenoses vs 32 in the control group), antichlamydial antibodies increased during follow-up(anti-CP IgG + 12± 2% , P< .001). Concentrations of TNF-α and eotaxin increased as well(TNF-α + 9± 1% and eotaxin + 10± 2% )and correlated with antichlamydial antibody concentrations(TNF-α , r=0.23, P=.02; eotaxin, r=0.32, P=.002). Conclusions: Treatment with roxithromycin was not associated with a reduction of symptomatic restenoses. During follow-up, a marked increase in antichlamydial antibodies, TNF-α , and eotaxin was observed, suggesting that angioplasty-induced plaque rupture induces a specific immunological response without activation of inflammatory mechanisms as represented by C-reactive protein. Whether this mechanism occurs in all plaque ruptures remains to be determined.
文摘目的：了解南昌大学第三附属医院耐碳青霉烯类抗菌药物的肺炎克雷伯菌（CRKP）的耐药状况。方法将2009年1月至2013年12月临床送检合格标本，采用西门子Micro Scan Walk Away40 Plus 微生物分析仪及配套的革兰阴性菌鉴定药敏板，进行菌株鉴定与药敏试验，结果判读按照CLSI的标准，将分离到的肺炎克雷伯菌进行筛选，再筛选出CRKP。结果从检测到的769株肺炎克雷伯菌中筛选到17株CRKP。 CRKP发生率2009年为0.0%，2013年上升到4.3%。CRKP对加替沙星耐药率最低占33.3％，对氨苄青霉素、阿莫西林/棒酸、头孢唑啉、环丙沙星、替卡西林/棒酸、耐药率高达100.0％；头孢类除孢噻肟、头孢哌酮/舒巴坦耐药率在50.0%以下，其余的均在50.0%～100.0%。美洛配能亚胺培南耐药率高达80.0%以上。结论 CRKP对常用抗菌药物有严重的耐药趋势，对重症患者、感染严重患者，不能单凭经验用药，应依据药敏试验选择抗菌药物。
